Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model by Babbs, A, Berg, A, Chatzopoulou, M, Davies, K, Davies, S, Edwards, B, Elsey, D, Emer, E, Figuccia, A, Fletcher, A, Guiraud, S, Harriman, S, Moir, L, Robinson, N, Rowley, J, Russell, A, Squire, S, Thomson, J, Tinsley, J, Wilson, F, Wynne, G

“…Herein we report the synthesis of SMT022357, a second generation utrophin modulator preclinical candidate, and an asymmetric synthesis of its constituent enantiomers. …”

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers by Tinsley, J, Robinson, N, Davies, K

“…SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. …”

Second-generation compound for the modulation of utrophin in the therapy of DMD by Guiraud, S, Squire, S, Edwards, B, Chen, H, Burns, D, Shah, N, Babbs, A, Davies, S, Wynne, G, Russell, A, Elsey, D, Wilson, F, Tinsley, J, Davies, K

“…These studies in the mdx mouse demonstrate that oral administration of SMT022357 leads to increased utrophin expression in skeletal, respiratory and cardiac muscles. …”

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. by Tinsley, J, Fairclough, R, Storer, R, Wilkes, F, Potter, A, Squire, SE, Powell, D, Cozzoli, A, Capogrosso, R, Lambert, A, Wilson, F, Wren, S, De Luca, A, Davies, K

“…Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. …”

A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric duchenne muscular dystrophy patients on a balanced diet by Muntoni, F, Tejura, B, Spinty, S, Roper, H, Hughes, I, Layton, G, Davies, K, Harriman, S, Tinsley, J

“…Ezutromid (SMT C1100) is a small-molecule utrophin modulator that was developed to treat Duchenne muscular dystrophy (DMD). …”